New data from ALXN1210 dose-escalation study show rapid and sustained reductions in LDH
Alexion announced new data from an ongoing Phase 1/2 dose-escalation study of ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria showed rapid and sustained reductions in lactate dehydrogenase, a direct marker of hemolysis, in patients treated with once-monthly dosing. December 04, 2016